OTTAWA, May 17, 2018 (GLOBE NEWSWIRE) -- Tetra Natural Health a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) and - Namaste Technologies Inc. (“Namaste” or the “Company”) (TSX-V:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company has signed a Supply Agreement ( the “Supply Agreement”) for the sale and distribution of Rx Princeps™ the medicinal cannabis brand of Tetra Natural Health, a division of Tetra Bio-Pharma  (“Tetra Bio-Pharma”)(TSX-V:TBP) (OTCQB:TBPMF), whereby Namaste will purchase Rx Princeps™  from Tetra Natural Health  which will be sold through Namaste’s wholly owned subsidiary Access to Cannabis for Medical Purposes (“ACMPR”) medical cannabis “sales-only” facility, Cannmart Inc. (“Cannmart”). The agreement also includes the sales of Tetra Natural Health’s specially designed inhalation device, air filters and its Munchies B Gone gum.

Guy Chamberland, Interim CEO and CSO of Tetra Bio-Pharma comments “We are thrilled to have signed this partnership deal with Namaste who operates as an E-Commerce Medicinal Cannabis distributor with 32 sites in 20 countries, providing substantial exposure for Tetra Natural Health’s Rx Princeps™ brand of premium medicinal cannabis.  We believe this is the making of a solid partnership with Tetra Natural Health’s ability to produce a quality product combined with Namaste’s far reaching sales and distribution network”.

Sean Dollinger, President and CEO of Namaste comments; “We are very proud to be bringing on a strong supply partner like Tetra Bio-Pharma. Rx Princeps™ is a unique pharma-based product that we feel will be very valuable for our patients. We have a unique opportunity to develop an exciting platform that will cater specifically to a patient’s needs. We plan on providing a single source for all things cannabis and Cannmart and NamasteMD are key components of that strategy along with securing the highest quality cannabis for our patients. We’d like to take the opportunity to thank Tetra Bio-Pharma management team for their support and look forward to a growing future together.”

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD).

About Tetra Bio Pharma

Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing cannabis and other medicinal plant-based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada's first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada's largest database of medical cannabis patients. The company's subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a "sales-only" license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

More information at: www.tetrabiopharma.com

For further information, please contact:
Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
[email protected]
C 514 817-2514

For media information, please contact:
Daniel Granger
[email protected]    
 ACJ Communication
O: 1 514 840 7990 
M: 1 514 232 1556

For more information from Namaste Technologies, please contact:
Sean Dollinger, President and Chief Executive Officer
Namaste Technologies Inc.
Direct: +1 (786) 389 9771
Email: [email protected]